JP5113979B2 - 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 - Google Patents
複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 Download PDFInfo
- Publication number
- JP5113979B2 JP5113979B2 JP2003572923A JP2003572923A JP5113979B2 JP 5113979 B2 JP5113979 B2 JP 5113979B2 JP 2003572923 A JP2003572923 A JP 2003572923A JP 2003572923 A JP2003572923 A JP 2003572923A JP 5113979 B2 JP5113979 B2 JP 5113979B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- sarm
- androgen receptor
- another embodiment
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[C@@](*)(COc(c(*)c(c(F)c1I)F)c1F)C(CCC=C*c1ccc(*)c(C(F)(F)F)c1)=O Chemical compound C[C@@](*)(COc(c(*)c(c(F)c1I)F)c1F)C(CCC=C*c1ccc(*)c(C(F)(F)F)c1)=O 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Description
薬剤は選択的アンドロゲンレセプタ修飾因子(SARM)化合物の新規なサブクラスを定める。複数のSARM化合物は、アンドロゲンレセプタのための非ステロイド性リガンドの、予想出来ないアンドロゲン活性及びタンパク同化活性を有することが解った。別のSARM化合物は、アンドロゲンレセプタのための非ステロイド性リガンドの予想できない抗アンドロゲン活性を有することが解った。それらSARM化合物は、単独で用いられても成分として用いられても、a)男性の避妊、b)高齢男性におけるアンドロゲン減少(ADAM)に関連するような、複数のホルモン関連コンディションの治療、例えば、うつ病、***減退、生殖機能不全、インポテンツ、性腺機能低下症、骨粗鬆症、脱毛症、貧血、肥満、サルコペニア、骨減少症、オステオポローシス、前立腺肥大症、認識及び気分の変化、及び前立腺癌、c)ADIFに関連するコンディションの治療、例えば、生殖機能不全、***減退、性腺機能低下症、サルコペニア、骨減少症、骨粗鬆症、認識及び気分の変化、貧血、脱毛症 肥満、子宮内膜症、乳ガン、子宮癌、及び卵巣癌、d)急性及び/または慢性の筋萎縮障害の治療及び/又は防止、e)ドライアイの治療及び/又は防止、f)経口アンドロゲン補充療法、及び/又はg)前立腺癌発生の減少、若しくは前立腺癌退行の中断若しくは実行に有用である。
薬剤は選択的アンドロゲンレセプタ修飾因子(SARM)化合物の新規なサブクラスを定める。複数のSARM化合物は、アンドロゲンレセプタのための非ステロイド性リガンドの、予想出来ないアンドロゲン活性及びタンパク同化活性を有することが解った。別のSARM化合物は、アンドロゲンレセプタのための非ステロイド性リガンドの予想できない抗アンドロゲン活性を有することが解った。それらSARM化合物は、単独で用いられても成分として用いられても、a)男性の避妊、b)高齢男性におけるアンドロゲン減少(ADAM)に関連するような、複数のホルモン関連コンディションの治療、例えば、うつ病、***減退、生殖機能不全、インポテンツ、性腺機能低下症、骨粗鬆症、脱毛症、貧血、肥満、サルコペニア、骨減少症、オステオポローシス、前立腺肥大症、認識及び気分の変化、及び前立腺癌、c)ADIFに関連するコンディションの治療、例えば、生殖機能不全、***減退、性腺機能低下症、サルコペニア、骨減少症、骨粗鬆症、認識及び気分の変化、貧血、脱毛症 肥満、子宮内膜症、乳ガン、子宮癌、及び卵巣癌、d)急性及び/または慢性の筋萎縮障害の治療及び/又は防止、e)ドライアイの治療及び/又は防止、f)経口アンドロゲン補充療法、及び/又はg)前立腺癌発生の減少、若しくは前立腺癌退行の中断若しくは実行に有用である。
ここに提供されているSARM化合物とは、アンドロゲンレセプタのための非ステロイド性リガンドのアンドロゲン活性及びタンパク同化活性のための予期不可能なin-vivo活性を有する経口のテストステロン置換療法に有用な選択的アンドロゲンレセプタ修飾因子(SARM)である化合物のことである。さらには、適切に置換された化合物は、イメージングのために前立腺癌治療に有用である。SARM化合物は、アンドロゲンレセプタのための非ステロイド性リガンドのin-vivoなアンドロゲン及びタンパク同化活性を実証する。
一実施例では、本発明は、5-αレダクターゼ阻害剤と結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、アロマターゼ阻害剤と結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、プロゲスチンと結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、他の核ホルモンレセプタを介して作用する薬剤と結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、選択的エストロゲンレセプタ修飾因子(SERM)結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、プロゲステロンと結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、エストロゲンと結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、PDE5インヒビタと結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、アポモルヒネと結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、ビスホスホネートと結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。一実施例では、本発明は、一つ若しくは複数の追加的SARMと結合した、選択的アンドロゲンレセプタ修飾因子を含む組成物を投与する過程を含む。
pH及びイオン強度、界面に対する吸収を防止するためのアルブミンもしくはゼラチンのような添加物、洗剤(トウィーン20、トウィーン80、Pluronic F68、胆汁酸塩)、可溶化剤(グリセリン、ポリエチレングリコール)、抗酸化剤(アスコルビン酸、メタ重亜硫酸ナトリウム)、防腐剤(チメロサール、ベンジルアルコール、パラオキシ安息香酸エステル類)、バルキング物質若しくは緊張修飾因子(例えばラクトース、マンニトール)、タンパク質に対するポリエチレングリコールのようなポリマーの共有結合、金属イオンとの複合体形成、若しくはポリ乳酸、ポリグリコール酸、ヒドロゲルのような、ポリマー化合物の粒子状製剤へ、又はリポソーム、マイクロエマルション、ミセル、単層若しくは多層状の小胞、血球影、若しくはスフェロプラストへの物質の取り込みを含む。そのような成分は、物理的状態、溶解度、安定性、in vivoな放出速度、及びin vivoな排除速度に影響を与えうる。制御され、維持された放出成分は親油性持効性製剤(脂肪酸、ワックス、オイル等)を含む。
実施例1−結合親和力
結合親和力は、He et al. Eur. J. Med Chem. (2002), 619-634 及び Mukherjee et al. Xenobiotica (1996), 26, 117-122に記載されているように決定された。
動物について。体重90〜100gの未成熟なオスのSDラットを米国インディアナポリス州のハーラン・バイオサイエンス社(Harlan Biosciences (Indianapolis, IN))から購入した。動物は、適宜食料及び水を与えながら12時間の明暗サイクルに維持された。動物実験計画書は、研究機関内の動物の管理および使用に関する委員会(Institutional Laboratory Animal Care and Use Committee)によって審査及び承認されたものである。
化合物1及び2
去勢されたラットモデル中の化合物1及び2のアンドロゲン作用及びタンパク同化作用は、与薬の14日後に調べられた。無処置対照(去勢されておらず、未治療)と去勢された対照(去勢され、未治療)が対照群として用いられた。
去勢されたラットモデル中の化合物7のアンドロゲン作用及びタンパク同化作用は、与薬の14日後に調べられた。無処置対照(去勢されておらず、未治療)と去勢された対照(去勢され、未治療)が対照群として用いられた。ラットは、0日目に去勢され、毎日DMSO/PEGを賦形剤として化合物7を皮下に投与された(0.05〜3mg/日)。ラットは最終日に安楽死させられ、アンドロゲン器官(前立腺及び精嚢)とタンパク同化器官(肛門挙筋)の湿重量(wet weight)が決定された。
Claims (5)
- 請求項1に記載の選択的アンドロゲンレセプタ修飾因子化合物、その立体異性体、又はそれらの医薬的に許容される塩を担体及び希釈液とともに含む組成物。
- 効果的な量の、請求項1に記載の選択的アンドロゲンレセプタ修飾因子化合物、その立体異性体、若しくはそれらの医薬的に許容される塩を担体及び希釈液とともに含む医薬品組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45373602P | 2002-02-28 | 2002-02-28 | |
US60/453,736 | 2002-02-28 | ||
US42338102P | 2002-11-04 | 2002-11-04 | |
US60/423,381 | 2002-11-04 | ||
PCT/US2003/003123 WO2003074449A2 (en) | 2002-02-28 | 2003-02-24 | Multi-substitued selective androgen receptor modulators and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010110335A Division JP2010180245A (ja) | 2002-02-28 | 2010-05-12 | 選択的アンドロゲンレセプタ修飾因子の結合方法及び使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005526741A JP2005526741A (ja) | 2005-09-08 |
JP2005526741A5 JP2005526741A5 (ja) | 2006-04-13 |
JP5113979B2 true JP5113979B2 (ja) | 2013-01-09 |
Family
ID=33422848
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003572923A Expired - Fee Related JP5113979B2 (ja) | 2002-02-28 | 2003-02-24 | 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 |
JP2010110335A Pending JP2010180245A (ja) | 2002-02-28 | 2010-05-12 | 選択的アンドロゲンレセプタ修飾因子の結合方法及び使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010110335A Pending JP2010180245A (ja) | 2002-02-28 | 2010-05-12 | 選択的アンドロゲンレセプタ修飾因子の結合方法及び使用方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7705182B2 (ja) |
EP (1) | EP1487458B1 (ja) |
JP (2) | JP5113979B2 (ja) |
KR (2) | KR20040101251A (ja) |
CN (1) | CN1700923B (ja) |
AT (1) | ATE533494T1 (ja) |
ES (1) | ES2528764T3 (ja) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
CA2648099C (en) | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
EP2019691B1 (en) | 2006-05-15 | 2020-08-12 | Massachusetts Institute of Technology | Polymers for functional particles |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
PT2054049E (pt) | 2006-08-24 | 2016-06-02 | Univ Tennessee Res Found | Acilanilidas substituídas e métodos de utilização das mesmas |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
EP2134830A2 (en) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oscillating cell culture bioreactor |
US20090074828A1 (en) | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
EP2205552B1 (en) * | 2007-09-11 | 2018-02-28 | GTx, Inc. | Crystalline polymorph of the selective androgen modulators (r) or (s)-n-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
PT2644594T (pt) | 2007-09-28 | 2017-11-20 | Pfizer | Direcionamento a células cancerosas utilizando nanopartículas |
JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
CA2787114A1 (en) * | 2010-01-11 | 2011-07-14 | Gtx, Inc. | Methods of treating meibomian gland dysfunction |
JPWO2012020806A1 (ja) | 2010-08-11 | 2013-10-28 | 旭硝子株式会社 | 撥水撥油剤組成物および物品 |
WO2012071340A1 (en) | 2010-11-23 | 2012-05-31 | Metamagnetics Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
PT2872482T (pt) | 2012-07-13 | 2020-09-22 | Oncternal Therapeutics Inc | Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
KR20190077607A (ko) * | 2014-10-16 | 2019-07-03 | 지티엑스, 인코포레이티드 | Sarm을 이용하는 비뇨기 장애의 치료 방법 |
CN106748884B (zh) * | 2016-12-13 | 2021-08-20 | 山西振东制药股份有限公司 | 一种比卡鲁胺中间体的制备方法 |
CN109134533B (zh) | 2017-06-27 | 2020-08-11 | 维眸生物科技(上海)有限公司 | 一种含磷化合物及其制备和应用 |
WO2019001171A1 (zh) * | 2017-06-27 | 2019-01-03 | 维眸生物科技上海有限公司 | 一种含磷化合物及其制备和应用 |
JP2021523151A (ja) | 2018-05-11 | 2021-09-02 | ホスホレックス、インコーポレイテッド | 負の表面電荷を有するマイクロ粒子及びナノ粒子 |
IL301906A (en) | 2020-10-08 | 2023-06-01 | Targimmune Therapeutics Ag | Immunotherapy for cancer treatment |
WO2023079142A2 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100044A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol |
WO2024100040A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100046A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024104422A1 (en) * | 2022-11-17 | 2024-05-23 | Vivavision Biotech, Inc. | Phosphorus-containing compounds for treating inflammatory bowel diesease |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB136001A (en) | 1919-01-11 | 1919-12-11 | Frank Harrison | An Adjustable Angle, and Surface-marking Plate. |
GB1360001A (en) | 1971-06-16 | 1974-07-17 | Scherico Ltd | Pharmaceutical compositions comprising substituted anilides |
US3875229A (en) * | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
JPS6044294B2 (ja) | 1976-04-15 | 1985-10-02 | 帝国臓器製薬株式会社 | アニリド誘導体 |
US4139638A (en) * | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
DE2862100D1 (en) * | 1977-10-12 | 1983-01-05 | Ici Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
US4191775A (en) | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
NZ197008A (en) * | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
LU88769I2 (fr) * | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
US4633025A (en) | 1985-04-15 | 1986-12-30 | Miles Laboratories, Inc. | Method for preparing (+)R-2-methyl-hexane-1,2-diol |
GB8617653D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
GB8617652D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
US4977288A (en) | 1988-01-29 | 1990-12-11 | President And Fellows Of Harvard College | M-aminophenyltrialkylstannane |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
CA2181358A1 (en) | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
DK0800519T3 (da) | 1994-12-22 | 2004-03-01 | Ligand Pharm Inc | Steroidreceptormodulatorforbindelser og fremgangsmåder |
US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
AU728178B2 (en) | 1996-06-27 | 2001-01-04 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
WO1998005962A1 (en) | 1996-08-02 | 1998-02-12 | Panvera Corporation | A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization |
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
WO1998053826A1 (en) * | 1997-05-30 | 1998-12-03 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
WO1998055153A1 (en) | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
RU2234920C2 (ru) | 1999-06-11 | 2004-08-27 | Уотсон Фармасьютикалс, Инк. | Введение непероральным путем андрогенных стероидов женщинам |
CA2388253A1 (en) | 1999-10-14 | 2001-04-19 | Bristol-Myers Squibb Company | Crystallographic structure of the androgen receptor ligand binding domain |
CA2387570A1 (en) | 1999-10-19 | 2001-04-26 | Nobex Corporation | Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof |
HUP0203186A2 (hu) | 1999-10-27 | 2003-01-28 | Nobex Corporation | Intermedierek rezolválása lényegében tiszta bicamlutamid szintézisében |
US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
RU2003102390A (ru) | 2000-06-28 | 2004-05-27 | Бристол-Маерс Сквибб Компани (Us) | Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения |
IL152719A0 (en) | 2000-06-28 | 2003-06-24 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification |
US6998500B2 (en) * | 2000-08-24 | 2006-02-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
PT1491524E (pt) * | 2000-08-24 | 2009-04-16 | Univ Tennessee Res Foundation | Moduladores selectivos do receptor androgénico e processos para a sua utilização |
IL154425A0 (en) * | 2000-08-24 | 2003-09-17 | Univ Tennessee Res H Corp | Selective androgen receptor modulators and methods of use thereof |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
PT1463497E (pt) * | 2001-12-06 | 2011-12-20 | Gtx Inc | Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios |
-
2003
- 2003-02-24 EP EP03743665A patent/EP1487458B1/en not_active Expired - Lifetime
- 2003-02-24 AT AT03743665T patent/ATE533494T1/de active
- 2003-02-24 KR KR10-2004-7013479A patent/KR20040101251A/ko active IP Right Grant
- 2003-02-24 CN CN038096064A patent/CN1700923B/zh not_active Expired - Fee Related
- 2003-02-24 KR KR1020107017179A patent/KR101088352B1/ko active IP Right Grant
- 2003-02-24 US US10/371,155 patent/US7705182B2/en not_active Expired - Fee Related
- 2003-02-24 JP JP2003572923A patent/JP5113979B2/ja not_active Expired - Fee Related
- 2003-02-24 ES ES10010264.9T patent/ES2528764T3/es not_active Expired - Lifetime
-
2010
- 2010-05-12 JP JP2010110335A patent/JP2010180245A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2010180245A (ja) | 2010-08-19 |
KR20040101251A (ko) | 2004-12-02 |
CN1700923A (zh) | 2005-11-23 |
JP2005526741A (ja) | 2005-09-08 |
US20060183931A1 (en) | 2006-08-17 |
US7705182B2 (en) | 2010-04-27 |
ATE533494T1 (de) | 2011-12-15 |
CN1700923B (zh) | 2011-06-15 |
EP1487458A2 (en) | 2004-12-22 |
EP1487458B1 (en) | 2011-11-16 |
ES2528764T3 (es) | 2015-02-12 |
KR20100103662A (ko) | 2010-09-27 |
EP1487458A4 (en) | 2006-07-26 |
KR101088352B1 (ko) | 2011-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5113979B2 (ja) | 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 | |
JP4764719B2 (ja) | ハロゲン化選択的アンドロゲン受容体調節剤及びその使用方法 | |
JP2006506318A (ja) | ハロアセトアミド若しくはアジ化物置換化合物及びその使用方法 | |
JP2005529952A (ja) | N架橋選択的アンドロゲン受容体修飾物質及びその使用方法 | |
US7803970B2 (en) | Multi-substitued selective androgen receptor modulators and methods of use thereof | |
JP2006506369A (ja) | メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法 | |
JP2006518328A (ja) | 複素環選択的アンドロゲン受容体調節剤及びその使用方法 | |
US20060229362A1 (en) | Selective androgen receptor modulators and methods of use thereof | |
MXPA04009460A (es) | Moduladores receptores de androgeno selectivo multi-sustituidos y metodos de uso de los mismos. | |
JP2006516286A (ja) | Sarmによる女性のアンドロゲン減少に関連する病気の治療 | |
JP2005519111A (ja) | 不可逆型選択的アンドロゲンレセプタ修飾因子及びその使用方法 | |
AU2008201811B2 (en) | Multi-substituted selective androgen receptor modulators and methods of use thereof | |
KR20040105208A (ko) | 할로아세트아미드 및 아지드 치환 화합물 및 그의 용도 | |
EP2266577A1 (en) | Multi-substitued selective androgen receptor modulators and methods of use therof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060222 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060222 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090713 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090908 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090915 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100618 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100623 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20101001 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120209 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20120724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120904 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121015 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151019 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5113979 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |